典型文献
Equivalent efficacy assessment of QL1101 and bevacizumab in nonsquamous non-small cell lung cancer patients:A two-year follow-up data update
文献摘要：
Objective:Anti-vascular endothelial growth factor(VEGF)monoclonal antibodies are an effective means of treating non-small cell lung cancer(NSCLC).Here,we aim to update the equivalent efficacy assessment between QL1101 and bevacizumab based on two-year follow-up data.Methods:In total,535 eligible NSCLC patients were enrolled in this randomized controlled trial.Patients were randomly assigned 1:1 to the QL1101 group and the bevacizumab group.The full end time of this study was defined as 24 months after the last enrolled patient was randomized.The primary endpoint was the objective response rate(ORR);equivalence was confirmed if the two-sided 90％confidence interval(90％CI)of the relative risk was within the range of 0.75-1.33.The secondary endpoints were progression-free survival(PFS)and overall survival(OS).Results:The two-year updated data showed similar ORR(QL1101 vs.bevacizumab:53.1％vs.54.3％;relative risk=0.977;90％CI:0.838-1.144),PFS(235 d vs.254 d,log-rank P=0.311),and OS(577 d vs.641 d,log-rank P=0.099)results between the QL1101 group and the bevacizumab group.The mean shrinkage ratio of targeted lesions was also similar between the QL1101 group and the bevacizumab group(22.5％vs.23.5％).For patients who received QL1101 maintenance therapy,similar results were shown between the QL1101 group(n=157)and the bevacizumab group(n=148)(PFS:253 d vs.272 d,log-rank P=0.387;OS:673 d vs.790 d,log-rank P=0.101;mean tumor shrinkage rate:26.6％vs.27.5％).Conclusions:This study reported that QL1101 had similar efficacy in treating nonsquamous NSCLC in terms of ORR,PFS and OS based on two-year updated data,providing a basis for the clinical application of QL1101.
文献关键词：
中图分类号：
作者姓名：
Jun Lu;Tianqing Chu;Hongyu Liu;Minjuan Hu;Yuqing Lou;Yanwei Zhang;Zhiqiang Gao;Wei Zhang;Xueyan Zhang;Huimin Wang;Hua Zhong;Baohui Han
作者机构：
Department of Pulmonary Medicine,Shanghai Chest Hospital,Shanghai Jiao Tong University,Shanghai 200030,China;Shanghai Institute of Thoracic Oncology,Shanghai Chest Hospital,Shanghai Jiao Tong University,Shanghai 200030,China;Translational Medical Research Platform for Thoracic Oncology,Shanghai Chest Hospital,Shanghai Jiao Tong University,Shanghai 200030,China;Department of Bio-bank,Shanghai Chest Hospital,Shanghai Jiao Tong University,Shanghai 200030,China
文献出处：
引用格式：
[1]Jun Lu;Tianqing Chu;Hongyu Liu;Minjuan Hu;Yuqing Lou;Yanwei Zhang;Zhiqiang Gao;Wei Zhang;Xueyan Zhang;Huimin Wang;Hua Zhong;Baohui Han-.Equivalent efficacy assessment of QL1101 and bevacizumab in nonsquamous non-small cell lung cancer patients:A two-year follow-up data update)[J].中国癌症研究（英文版）,2022(01):28-39
A类：
QL1101,nonsquamous
B类：
Equivalent,efficacy,assessment,bevacizumab,small,cell,lung,cancer,patients,two,year,follow,data,Objective,Anti,vascular,endothelial,growth,VEGF,monoclonal,antibodies,are,effective,means,treating,NSCLC,Here,aim,equivalent,between,Methods,In,total,eligible,were,enrolled,this,randomized,controlled,trial,Patients,randomly,assigned,group,full,study,was,defined,months,after,last,primary,objective,response,rate,ORR,equivalence,confirmed,if,sided,confidence,interval,relative,risk,within,range,secondary,endpoints,progression,free,survival,PFS,overall,OS,Results,updated,showed,similar,log,rank,results,shrinkage,ratio,targeted,lesions,also,For,who,received,maintenance,therapy,shown,tumor,Conclusions,This,reported,that,had,terms,providing,basis,clinical,application
AB值：
0.416622
相似文献
机标中图分类号，由域田数据科技根据网络公开资料自动分析生成，仅供学习研究参考。
